P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Drug: P1101 (Ropeginterferon alfa-2b);   Drug: Nivolumab Sponsors:   National Taiwan University Hospital;   PharmaEssentia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials